STOCK TITAN

DSS (DSS) director-linked entities report $2.45M note and 16.6M-share warrant

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

DSS, INC. reported an indirect restructuring-type transaction involving entities associated with director and ten percent owner Chan Heng Fai Ambrose. Alset International Limited holds a $2,450,000 Convertible Promissory Note that became convertible into common stock at $0.74 per share on June 3, 2026. On March 26, 2026, Alset International Limited also received common stock purchase warrants to buy up to 16,554,055 DSS common shares at an exercise price of $0.93 per share, expiring on March 26, 2031. The filing notes these positions as indirectly beneficially owned through entities controlled by Mr. Chan.

Positive

  • None.

Negative

  • None.
Insider Chan Heng Fai Ambrose, Alset Inc., Alset International Ltd
Role null | null | null
Type Security Shares Price Value
Other Convertible Promissory Note 0 $0.74 --
Other Common Stock Purchase Warrant 16,554,055 $0.93 $15.40M
Holdings After Transaction: Convertible Promissory Note — 0 shares (Indirect, See footnote); Common Stock Purchase Warrant — 16,554,055 shares (Indirect, See footnote)
Footnotes (1)
  1. On March 26, 2026 the Issuer issued a convertible promissory note (the "Convertible Promissory Note") to Alset International Limited in the amount of $2,450,000, which became convertible on June 3, 2026. Under the terms of the Convertible Promissory Note, Alset International Limited may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of either (i) $0.74 per share, or (ii) if while the Convertible Promissory Note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the Convertible Promissory Note, the Holder may elect to exchange the Convertible Promissory Note for such convertible instrument based on the Convertible Promissory Note's principal balance plus any accrued but unpaid interest. On March 26, 2026 the Issuer issued common stock purchase warrants (the "Warrants") to Alset International Limited to purchase up to 16,554,055 shares of the Issuer's common stock at an exercise price of $0.93 per share. The Warrants expire on March 26, 2031. The beneficial ownership of Mr. Chan as of the date hereof may be deemed to include the following shares held personally (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of the Issuer's common stock held by Mr. Chan directly. Mr. Chan may also be deemed to beneficially own (a) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (b) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (c) 1,068,309 shares of the Issuer's common stock, a convertible promissory note in the amount of $2,450,000, and common stock purchase warrants to purchase up to 16,554,055 shares held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (d) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).
Convertible note principal $2,450,000 Convertible Promissory Note issued to Alset International Limited
Note conversion price $0.74/share Conversion price into DSS common stock
Warrant shares 16,554,055 shares Common stock purchase warrants held by Alset International Limited
Warrant exercise price $0.93/share Exercise price for DSS common stock under the warrants
Warrant expiration March 26, 2031 Expiration date of DSS common stock purchase warrants
Restructuring-related shares 16,554,055 shares Shares tied to restructuring-type derivative transactions (code J)
Convertible Promissory Note financial
"the Issuer issued a convertible promissory note (the "Convertible Promissory Note")"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
common stock purchase warrants financial
"the Issuer issued common stock purchase warrants (the "Warrants") to Alset International Limited"
Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.
beneficially own financial
"The beneficial ownership of Mr. Chan as of the date hereof may be deemed to include"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
ten percent owner financial
"reporting persons include a director and ten percent owner of the Issuer"
indirect ownership financial
"total_shares_following_transaction marked as indirect with nature of ownership "See footnote""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions were reported for DSS (DSS) in this Form 4?

DSS reported an indirect restructuring-type transaction involving entities linked to director Chan Heng Fai Ambrose. A Convertible Promissory Note became convertible, and related warrants to purchase up to 16,554,055 common shares at $0.93 per share were disclosed.

What are the key terms of the DSS (DSS) Convertible Promissory Note?

The Convertible Promissory Note totals $2,450,000 and is held by Alset International Limited. It became convertible on June 3, 2026 into DSS common stock at a conversion price of $0.74 per share, based on outstanding principal and accrued interest.

How many DSS (DSS) shares can be purchased under the warrants disclosed?

The warrants allow purchase of up to 16,554,055 DSS common shares. They were issued to Alset International Limited with an exercise price of $0.93 per share and an expiration date of March 26, 2031, providing a long-dated potential equity position.

Who holds the DSS (DSS) note and warrants reported in this Form 4?

Alset International Limited holds the Convertible Promissory Note and warrants. The filing explains this entity is controlled by Chan Heng Fai Ambrose, so these securities are reported as indirectly beneficially owned through entities associated with him.

What does the "J" transaction code mean in the DSS (DSS) Form 4?

The "J" transaction code indicates another type of acquisition or disposition rather than a straightforward open-market buy or sell. Here it reflects the reporting of restructuring-type positions in a convertible note and related warrants held indirectly through controlled entities.

What additional DSS (DSS) holdings are attributed to Chan Heng Fai Ambrose?

The filing lists various common share holdings and other instruments across entities controlled by Mr. Chan. These include personally held shares, shares and a separate $500,000 convertible note at Alset Inc., and additional shares at Global Biomedical Pte. Ltd.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chan Heng Fai Ambrose

(Last)(First)(Middle)
9 TEMASEK BOULEVARD
#16-04 SUNTEC TOWER TWO

(Street)
SINGAPORE038989

(City)(State)(Zip)

SINGAPORE

(Country)
2. Issuer Name and Ticker or Trading Symbol
DSS, INC. [ DSS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Convertible Promissory Note(1)(1)06/03/2026J$2,450,000(1)06/03/202603/26/2031Common Stock(1)$0.74(1)$2,450,000(3)(4)ISee footnote(3)(4)
Common Stock Purchase Warrant(2)06/03/2026J16,554,055(2)06/03/202603/26/2031Common Stock16,554,055(2)$0.93(2)16,554,055(3)(4)ISee footnote(3)(4)
1. Name and Address of Reporting Person*
Chan Heng Fai Ambrose

(Last)(First)(Middle)
9 TEMASEK BOULEVARD
#16-04 SUNTEC TOWER TWO

(Street)
SINGAPORE038989

(City)(State)(Zip)

SINGAPORE

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Alset Inc.

(Last)(First)(Middle)
4800 MONTGOMERY LANE
SUITE 210

(Street)
BETHESDA MARYLAND 20814

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Alset International Ltd

(Last)(First)(Middle)
9 TEMASEK BOULEVARD
#16-04 SUNTEC TOWER TWO

(Street)
SINGAPORE038989

(City)(State)(Zip)

SINGAPORE

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. On March 26, 2026 the Issuer issued a convertible promissory note (the "Convertible Promissory Note") to Alset International Limited in the amount of $2,450,000, which became convertible on June 3, 2026. Under the terms of the Convertible Promissory Note, Alset International Limited may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of either (i) $0.74 per share, or (ii) if while the Convertible Promissory Note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the Convertible Promissory Note, the Holder may elect to exchange the Convertible Promissory Note for such convertible instrument based on the Convertible Promissory Note's principal balance plus any accrued but unpaid interest.
2. On March 26, 2026 the Issuer issued common stock purchase warrants (the "Warrants") to Alset International Limited to purchase up to 16,554,055 shares of the Issuer's common stock at an exercise price of $0.93 per share. The Warrants expire on March 26, 2031.
3. The beneficial ownership of Mr. Chan as of the date hereof may be deemed to include the following shares held personally (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of the Issuer's common stock held by Mr. Chan directly.
4. Mr. Chan may also be deemed to beneficially own (a) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (b) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (c) 1,068,309 shares of the Issuer's common stock, a convertible promissory note in the amount of $2,450,000, and common stock purchase warrants to purchase up to 16,554,055 shares held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (d) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).
/s/ Heng Fai Ambrose Chan07/09/2026
Alset Inc. /s/ Heng Fai Ambrose Chan, Chief Executive Officer07/09/2026
Alset International Limited /s/ Heng Fai Ambrose Chan, Chief Executive Officer07/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)